AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|AAPL332.41+1.07 (+0.32%) ▲|ABBV262.51-0.53 (-0.20%) ▼|ABT102.36+0.33 (+0.32%) ▲|ACN189.64-3.76 (-1.94%) ▼|ADBE250.50-7.26 (-2.82%) ▼|AMAT415.38-5.79 (-1.37%) ▼|AMD512.50+8.30 (+1.65%) ▲|AMGN376.35+0.70 (+0.19%) ▲|AMT176.39-1.32 (-0.74%) ▼|AMZN245.96-2.46 (-0.99%) ▼|AVGO339.51+0.24 (+0.07%) ▲|AXP312.43-12.00 (-3.70%) ▼|BA201.96-7.73 (-3.69%) ▼|BAC57.90-1.62 (-2.72%) ▼|BKNG171.40+0.08 (+0.05%) ▲|BLK1,037.24-21.42 (-2.02%) ▼|BMY63.60-0.13 (-0.20%) ▼|BNY153.47-1.20 (-0.78%) ▼|BRK-B519.80+3.04 (+0.59%) ▲|C132.95-3.22 (-2.36%) ▼|CAT782.72-0.82 (-0.10%) ▼|CL87.02+0.02 (+0.02%) ▲|CMCSA23.73-0.69 (-2.83%) ▼|COF203.19-3.66 (-1.77%) ▼|COP132.54-8.68 (-6.15%) ▼|COST893.74-7.61 (-0.84%) ▼|CRM250.54-5.11 (-2.00%) ▼|CSCO107.74-2.33 (-2.12%) ▼|CVS91.72-2.77 (-2.93%) ▼|CVX211.54-6.23 (-2.86%) ▼|DE669.47-14.57 (-2.13%) ▼|DHR208.36-1.00 (-0.48%) ▼|DIS106.99+0.57 (+0.54%) ▲|DUK117.76-0.01 (-0.01%) ▼|EMR145.83-1.17 (-0.80%) ▼|FDX301.72-6.54 (-2.12%) ▼|GD360.00+1.40 (+0.39%) ▲|GE312.90+5.85 (+1.91%) ▲|GEV925.09+42.28 (+4.79%) ▲|GILD147.68+1.38 (+0.94%) ▲|GM84.29-1.08 (-1.27%) ▼|GOOG339.36-2.07 (-0.61%) ▼|GOOGL342.87-2.11 (-0.61%) ▼|GS937.98-38.69 (-3.96%) ▼|HD302.47-3.01 (-0.99%) ▼|HON207.66+4.22 (+2.07%) ▲|IBM237.49-10.88 (-4.38%) ▼|INTC101.05+3.91 (+4.03%) ▲|INTU318.13-11.14 (-3.38%) ▼|ISRG382.29+5.13 (+1.36%) ▲|JNJ267.28+0.08 (+0.03%) ▲|JPM348.92-3.57 (-1.01%) ▼|KO87.87-0.84 (-0.95%) ▼|LIN462.09-0.87 (-0.19%) ▼|LLY1,137.82+1.71 (+0.15%) ▲|LMT537.25+3.79 (+0.71%) ▲|LOW194.10-0.51 (-0.26%) ▼|LRCX269.23-1.64 (-0.61%) ▼|MA567.75-5.52 (-0.96%) ▼|MCD248.56-4.22 (-1.67%) ▼|MDLZ62.36+0.26 (+0.42%) ▲|MDT92.60-1.15 (-1.23%) ▼|META673.31+3.07 (+0.46%) ▲|MMM162.65-2.02 (-1.23%) ▼|MO70.10+0.29 (+0.42%) ▲|MRK144.91+1.12 (+0.78%) ▲|MS202.42-3.86 (-1.87%) ▼|MSFT490.30-6.82 (-1.37%) ▼|MU926.55-1.05 (-0.11%) ▼|NEE80.37-0.70 (-0.86%) ▼|NFLX76.41-1.49 (-1.91%) ▼|NKE35.78-0.44 (-1.21%) ▼|NOW139.82-2.08 (-1.47%) ▼|NVDA213.90+1.73 (+0.82%) ▲|ORCL143.16+2.81 (+2.00%) ▲|PEP134.34-1.16 (-0.86%) ▼|PFE27.46-0.09 (-0.33%) ▼|PG147.02+0.35 (+0.24%) ▲|PLTR174.34+1.78 (+1.03%) ▲|PM191.71-2.40 (-1.24%) ▼|QCOM184.84-2.96 (-1.58%) ▼|RTX196.83+1.33 (+0.68%) ▲|SBUX97.34+0.76 (+0.79%) ▲|SCHW105.16-2.63 (-2.44%) ▼|SO86.23+0.28 (+0.33%) ▲|SPG202.94-1.16 (-0.57%) ▼|T25.86-0.86 (-3.22%) ▼|TMO648.43+7.04 (+1.10%) ▲|TMUS176.26-4.21 (-2.33%) ▼|TSLA358.08+1.50 (+0.42%) ▲|TXN260.67-2.76 (-1.05%) ▼|UBER70.97-0.46 (-0.64%) ▼|UNH375.26-0.67 (-0.18%) ▼|UNP280.92-3.07 (-1.08%) ▼|UPS98.77-3.58 (-3.50%) ▼|USB59.73-2.49 (-4.00%) ▼|V370.93-4.69 (-1.25%) ▼|VZ49.76-1.69 (-3.28%) ▼|WFC87.05-2.67 (-2.98%) ▼|WMT107.50-0.59 (-0.55%) ▼|XOM163.32-6.00 (-3.54%) ▼|
23.4 C
New York
Thursday, September 17, 2026

Tag: Complex

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Certified and Profitable: AIXA Miner Redefines Passive Crypto Income After FinCEN Approval

Colorado, USA, June 21, 2025 (GLOBE NEWSWIRE) -- Certified and profitable: AIXA Miner redefines passive crypto income following FinCEN approval

AIXA Miner, a leading crypto cloud mining platform, has officially secured its FinCEN Money Services Business (MSB) certification, becoming one of the few fully regulated mining platforms in the U.S. This regulatory milestone has rapidly boosted investor confidence—particularly among U.S. users—and helped expand AIXA Miner’s global user base to over 5 million active miners.

Analyzing Annuities’ Reputation: Evaluating Their Role in Strategic Financial Planning

Running out of money in retirement is a significant concern among investors, often surpassing even the fear of death. While maximizing contributions to an...

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

INVESTOR NOTICE: Apple Inc. (AAPL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Robbins Geller

SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Apple Inc. (NASDAQ: AAPL) securities between June 10, 2024 and June 9, 2025, inclusive (the “Class Period”), have until August 19, 2025 to seek appointment as lead plaintiff of the Apple class action lawsuit. Captioned Tucker v. Apple Inc., No. 25-cv-05197 (N.D. Cal.), the Apple class action lawsuit charges Apple and certain of Apple’s top current and former executives with violations of the Securities Exchange Act of 1934.

Lynch Carpenter Investigates Claims in Philadelphia Insurance Companies Data Breach

PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Philadelphia Insurance Companies (“PHYL”) recently announced a cybersecurity incident that resulted in the disruption of PHYL’s network operations across its systems. PHYL’s investigation into the incident is ongoing, and further details have not been made publicly available by PHYL.1

Lynch Carpenter Investigates Claims in Aflac Data Breach

PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Aflac Incorporated (“Aflac”) recently announced a cybersecurity incident, which impacted the personal information of an unknown number of individuals. The information potentially impacted in the data breach includes the claims information, health information, Social Security numbers, and other personal information of customers, beneficiaries, employees, agents, and other individuals.

Johnson Pope Expands Legal Talent with the Addition of Jessica Warwick and Samuel C. Craig to Its St. Petersburg Office

ST. PETERSBURG, Fla., June 20, 2025 /PRNewswire/ -- Johnson, Pope, Bokor, Ruppel & Burns, LLP is proud to announce the addition of two new associate...

Artificial Intelligence (A.I.) in Life Science: New Survey of 408 Researchers Reveals Split Sentiment, Surging Adoption, and Rising Trust Barriers

ARLINGTON, Va., June 20, 2025 /PRNewswire/ -- New survey data from 408 global scientists and researchers reveals a rapid increase in AI adoption—alongside mounting hesitation...

The Ensign Group, Inc. Announces Retirement of Its Executive Chairman

SAN JUAN CAPISTRANO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that Christopher Christensen, Executive Chairman and member of the Ensign Board of Directors, has provided notice to the board of his intent to retire from both his roles effective September 1, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsComplex